

# CURRICULUM VITAE

**NAME** : Mircea DEDIU

**INSTITUTION** : SANADOR Clinical Hospital

Address : Str Sevastopol nr 9, Sector 1, Bucharest, Romania

E mail : [dedium@sanador.ro](mailto:dedium@sanador.ro)

## **PRESENT POSITION**

- Chief of Medical Oncology Department

## **FORMER POSITION**

- Institute of Oncology Bucharest : Chief of Medical Oncology Department

## **MEDICAL DEGREES AND ACADEMIC TITLES**

- medical oncology senior consultant
- PhD
- Correspondent member of The Romanian Academy of Medical Sciences
- Senior scientific researcher

## **INTERNATIONAL RECOGNITION**

- **Certification of professional level at European standards :**
  - *Confirmed by ESMO scientific Committee as Certified member* of European Society of Medical Oncology after successful examination, Hamburg ,20 Oct 2000.
- **Full member of international medical societies**
  - American Society of Clinical Oncology : membership ID 34465
  - European Society of Medical Oncology : member ID 1606
  - International Association for the Study of Lung Cancer : membership ID 234133
  - European Organization For Research and Treatment of Cancer : Inst 6052
  -
- **International board position**
  - Romanian National Representative at European Society of Medical Oncology 2004-2011
  - Member of Board of Directors in Balkan Union of Oncology 2000-2012
- **Editorial board member : International journals**
  - Journal of BUON, Official Journal of Balkan Union of Oncology, indexed PubMed, Zebrinis Medical Publications, Athens, Greece, ISSN 1107-0625
  - Memo –magazine of European medical oncology- Official journal of the Central European cooperative Oncology Group (CECOG), SpringerWien new York Wien, ISSN 1865-5041

## **Professional training and experience**

1972-1975	Secondary School "I. L. Caragiale" Bucharest
1975-1981	Studies at Medicine Faculty in Bucharest
1981	Diploma work "The lung functional explorations in establishing the precocious diagnosis of chronic obstructive lung disease by irritant pollution "
1981	Graduation of Medicine Faculty in Bucharest
1982-1984	Medical training as "Intern" in the Clinical Hospital Colentina Bucharest
1984- 1988	Medical activity as general practitioner in village surgery ( Buzau and Giurgiu county)
1989-1991	Training period (physician in training) in medical oncology, clinical practice and research activity in the Medical Oncology Department of "The Institute of Oncology Bucharest"
1991	Confirmation as Scientific Researcher at The Institute of Oncology Bucharest,
1991	Confirmation as Medical Oncology consultant at "The Institute of Oncology Bucharest" (Medic specialist)
1996	Confirmation as Medical Oncology senior consultant at The Institute of Oncology Bucharest (medic primar)
1998	Confirmation as senior scientific researcher at The Institute of Oncology Bucharest.
2001	Institute of Oncology Bucharest PhD. Presented work : "Improving the chemo-irradiation treatment with or without surgery for stage III A non-small cell lung cancer "
2002 – 2013	Principal Investigator phase II, III, IV multicenter international clinical trials
2002- 2015	Chief of medical Oncology Department, Institute of Oncology Bucharest
<b>Since 2015</b>	<b>Chief of medical Oncology Department at The SANADOR Hospital</b>

## **FOREIGN LANGUAGES (FLUENT)**

- English
- French

# Publications in international journals

## Report from Web of Science Thompson Reuters


Web of Science Clarivate Analytics

Search Search Results My Tools Search History Marked List

Citation report for 67 results from Web of Science Core Collection between 1900 and 2018

You searched for: Article Group for: Dediu M\* ...[More](#)

This report reflects citations to source items indexed within Web of Science Core Collection. Perform a Cited Reference Search to include citations to items not indexed within Web of Science Core Collection.



### **FULL TEXT PAPERS ( see attached )**

### **ABSTRACTS (see attached)**

### **Books**

1. GUIDELINE FOR DIAGNOSIS AND TREATMENT OF THE LUNG CANCER  
Edited by **Mircea Dediu**

**Contents:** 1.Foreward for the readers. 2.Introduction. 3.Diagnostic and staging of the lung cancer 4.TNM classification. 5.State of the Art for small cell lung cancer. 6.State of the Art for non-small cell lung cancer. 7.Associates treatments for the patient with lung cancer .

Copyright by " Editura Inedit". Bucuresti, 1999, ISBN 973-96829-7-9 ; 48 pp

2. BRONCHOPULMONARY CANCER.  
Edited by T. Horvat, **M. Dediu**, A. Tarlea.

Contents and Contributors : Forward for the readers; *G. Rosti*. 1.Epidemiology of the lung cancer; *A. Tarlea*. 2. Tumor markers and genetic disorders of the lung cancer; *M. Dediu et al*. 3. Pathology of the lung cancer; *P. Galbenu*. 4. Clinical diagnosis of the lung cancer; *T. Horvat et al*. 5. Imagistic diagnosis of the lung cancer; *C. Zaharia et al*.6.Bronchoscopic evaluation of the lung cancer; *E. Crisan*. 7. Invasive investigations for staging of lung cancer; *I. Cordos et al*. 8. Pathologic examinations for the lung cancer; *P. Galbenu*. 9. TNM classification of lung cancer; *C. Savu et al*. 10. Surgical treatment for the lung cancer; *T. Horvat et al*. 11. Endoscopic treatments for lung cancer; *E. Crisan*. 12. Radiation therapy of the lung cancer; *A. Tarlea*. 13. Chemotherapy for non-small cell lung cancer; *M. Dediu*. 14. Chemotherapy for small cell lung cancer; *M. Dediu*. 15. Combined modality treatment for non-small cell lung cancer; *T. Horvat et al*. 16. Combined modality treatment for small cell lung cancer; *M. Dediu et al*. 17. Lung cancer chemoprevention; *M. Dediu*.

Copyright by "Editura Universul" , Bucuresti, 2000. ISBN 973-9027-55-5 ; 392 pp.

### 3. LUNG CANCER. DIAGNOSTIC AND THERAPEUTIC GUIDELINES

**M. Dediu**, T. Horvat, R. Anghel, A. Tarlea.

Contents: Epidemiology and risk factors. Diagnostic procedures. TNM staging. Therapeutic recommendations for NSCLC : Stage 0, Stage I and II, Stage III, stage IV. Therapeutic recommendations for SCLC: limited stage, extensive stage. Post therapeutic follow up. References.

Copyright by "Editura Universul" , Bucuresti, 2003, ISBN 973-9027-69-5; pp: 49.

### 4. ADJUVANT CHEMO-HORMONAL THERAPY IN BREAST CANCER. A PRACTICAL GUIDELINE.

**M. Dediu**, R. Anghel.

Contents : 1. Generalities. 2. Classification of patients according to risk factors. 3. Schematic representation of multimodal treatment in mammary carcinoma, stage I, II. 4. Adjuvant chemotherapy. 5. Taxanes in adjuvant treatment. 6. Neoadjuvant chemotherapy. 7. Adjuvant hormonal therapy. 8. Side effects associated with hormonal therapy. 9. Role of aromatase inhibitors as adjuvant hormonal treatment for estrogen receptor positive patients, in post-menopause. 10. Issues of chimio- hormonal association. 11. Chemo with or without hormonal therapy for patients with unknown hormonal receptors. 12. Timing of chemotherapy according to radiation. 12. Conclusions regarding the adjuvant treatment of breast cancer. Chemotherapy schedules used in adjuvant treatment of breast cancer.  
Copyright by "Editura Universul" , Bucuresti, 2004, ISBN 973-9027-79-2;  
pp : 99.

### 5. New staging system and recent trends in the systemic treatment of the breast cancer

**M. Dediu**, R. Anghel, D. Nutu, E. Busila, A. Silaghi, S. Donea, M. Iftimie,  
D. Spataru, G. Miron

Copyright by "Editura DAYA Satu Mare" , Satu Mare, 2005,  
ISBN 973- 7756- 04-5; pp : 285

## ***PARTICIPANT AUTHOR***

### 1. TREATMENT OF TUMOR RELAPSES WITH NEW AGENTS IN SMALL CELL LUNG CANCER

**M. Dediu**

**2<sup>nd</sup> Balkan Congress of Oncology,( Izmir-Turkey – September 10-14 1998)** pp:277-280

Editor George Antypas (President of BUON),Copyright 1998 by MONDUZZI EDITORE S.p.A. International Proceedings Division, Bologna, Italy.

### 2. BRONCHOPULMONARY CARCINOMA

T. Ciuleanu, **M. Dediu**, N. Ghilezan ,

in Practical Guidelines in Medicine, edited by Romanian Physicians Collegium, 2001, pp 77-101. ISBN : 973-9394-32-9, 073-9394-69-8.

3. CHEMOTHERAPY OF SUPERIOR VENA CAVA SYNDROME  
**M. Dediu**  
 , in T. Horvat, A. Cornea: The Superior Vena Cava Syndrome, Editura Universul  
 2003, pp :145-160. ISBN 973-9027-75-X.
4. Patient outcome following adjuvant chemotherapy (CT) in completely resected stage I-  
 IIIB, non-small cell lung cancer (NSCLC)  
**M. Dediu**, T. Horvat, R. Anghel, A Tarlea, A. Alexandru, D. Median,  
 C Nistor, A Ciuche, C Savu and P. Iorga.. in Zatloukal P, Petruzelka L  
 editors, International Proceedings of the 10<sup>th</sup> Central European Lung  
 Cancer Conference, Monduzzi Editore ISBN 88-7587-250-3, Bologna,  
 2006; 31-36.
5. Chemotherapy for resectable non-small cell lung cancer: It's time for a change in the  
 current paradigm  
 Mircea Dediu, Aurelia Alexandru, Dragos Median, Georgeta Vremes  
 in Lung cancer current status and perspectives 2005; pp:61-89 ISSN: 1107-0625

### Oral presentations in international meetings

1. New concepts in the era of Immune Check point inhibitors (PACIFIC).M. Dediu. CECOG  
 Academy, Lung Cancer, 2-3 November 2017, Vienna
2. Unsantifying the Sanctuary : challenges and opportunities with brain metastases . M.  
 Dediu. CECOG Academy, Lung Cancer, 2-3 November 2017, Vienna.
3. Current status of docetaxel in advanced hormone sensitive prostate cancer.  
 M. Dediu  
 2<sup>nd</sup> South East European Prostate Cancer Forum, 23-24 Feb 2017, Zagreb, Croatia
4. How to read clinical trials-take home messages for the clinician.  
 M. Dediu  
 Central European Initiative against Lung Cancer. 5<sup>th</sup> Expert Forum. 01 April 2017, Prague,  
 Czech, Republic
5. Current status and further perspectives in the treatment of EGFR mutant non-small cell  
 lung cancer.  
 M. Dediu  
 The 10th Annual World Cancer Congress, 19-21 may 2017, Barcelona, Spain,
6. Second line treatment in advanced NSCLC.  
**M. Dediu**  
 The 2015 Controlling Cancer Summit 12<sup>th</sup>-14<sup>th</sup> May 2015 London, UK
7. Case Discussions: Optimal Diagnosis and Treatment of ALK+ NSCLC Patients  
**M. Dediu** .  
 14th Central European Lung Cancer Conference. Vienna ,29.11.-02.12.2014.
8. LUME-Lung 1/ Nintedanib update  
**M. Dediu.**  
 14th Central European Lung Cancer Conference. Vienna ,29.11.-02.12.2014
9. "LUME Lung 2 – exploratory finding of a clinical biomarker which was prospectively  
 investigated and validated with positive Lume Lung 1 results  
**M. Dediu.**  
 Central European Initiative against lung cancer. Expert Forum . Vienna.16- 17.03.2014
10. "How to diagnose and manage NSCLC with the new drugs" - an interactive session: To  
 continue or not to continue, that is the question?

**M.Dediu**

European Respiratory Society Congress, Vienna, 2 September 2012

11. Impact of adjuvant chemotherapy in stage IB non-small cell lung cancer. An analysis of 112 consecutively treated patients.  
**M. Dediu**, 12 Central-European Lung Cancer Conference, Budapest, Hungary, 2-4 December 2010
12. Controversies around the use of the monoclonal antibodies in the treatment of advanced non-small cell lung cancer  
**M. Dediu**, 3rd BSO Seminar, Volos, Greece, 10-12 September 2009.
13. Breast Cancer: Adjuvant Endocrine Therapy of the Future.  
**M. Dediu**, 7th Congress of the Balkan Union of Oncology; Kusadasi, Turkey, 15-19 October 2008
14. MANAGEMENT OF PATIENTS WITH NSCLC IN PROGRESSION AFTER 1ST LINE CHEMOTHERAPY  
**M. Dediu**, 11th CELCC, Ljubljana, Slovenia; 12-14 June 2008, Ljubljana, Slovenia
15. EGFR-tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib  
**M. Dediu**, Balkan School Of Oncology 2, Volos, Greece 6-8 September 2007
16. The tyrosine kinase inhibitors: a new therapeutic avenue in non-small cell lung cancer  
**M. Dediu**, 6th CONGRESS OF THE BALKAN UNION OF ONCOLOGY, Sofia, Bulgaria, 13-16 September 2006
17. Confounding factors influencing patients' compliance with adjuvant chemotherapy (CT) in resected non-small cell lung cancer (NSCLC). A multivariate analysis  
**M. Dediu**, 6th CONGRESS OF THE BALKAN UNION OF ONCOLOGY, Sofia, Bulgaria, 13-16 September 2006
18. Atelectasis as a good prognostic factor for locally advanced non-small cell lung cancer  
**M. Dediu**, 6th CONGRESS OF THE BALKAN UNION OF ONCOLOGY, Sofia, Bulgaria, 13-16 September 2006
19. Patient Outcome Following Adjuvant Chemotherapy (CT) in Completely Resected, Stage I-IIIb, Non-Small Cell Lung Cancer (NSCLC)  
**M. Dediu**, 10<sup>th</sup> Central European Lung Cancer Conference, Prague, Czech Republic, 10 March 2006
20. Chemotherapy for resectable non-small cell lung cancer. It's time for a change in the current paradigm.  
**M. Dediu**, First educational course of BSO, Volos, Greece, 16-17 September 2005
21. Adjuvant and Neoadjuvant Chemotherapy in NSCLC  
**M. Dediu** European Lung Cancer Experts Board, Vienna, Austria, 24-25 November 2005
22. Cisplatin based adjuvant chemotherapy in completely resected non-small cell lung cancer. (Oral presentation OP98).  
**M. Dediu**, T. Horvat, A. Tarlea, R. Anghel, G. Miron. Fifth Congress of The Balkan Union of Oncology (BUON), 14-17 October, 2004, Belgrade, Serbia and Montenegro.
23. Adjuvant chemotherapy in the non-small cell lung cancer (Oral presentation).

**M. Dediu.** Symposium : New approaches in the diagnosis and treatment of non-small cell lung cancer. Fifth Congress of The Balkan Union of Oncology (BUON), 14-17 October ,2004, Belgrade, Serbia and Montenegro. Proceedings/educational book. Balkan union of oncology. C-129.

24. Chemotherapy around surgery: Pre or Post-operative  
**M. Dediu,** Congress of the Balkan Union of Oncology nov.22-23, 2002 Athens
25. Current situation of oncology in Romania  
M. Dediu, Congress of the Balkan Union of Oncology nov.22-23, 2002 Athens

### ***Principal investigator, international multicenter clinical trials***

1. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Prof Nick Thatcher, FRCPa, Fred R Hirsch, MD, Alexander V Luft, MD, Aleksandra Szczesna, MD, Prof Tudor E Ciuleanu, MD, **Mircea Dediu**, MD, Prof Rodryg Ramlau, MD, Rinat K Galiulin, MD, Beatrix Bálint, MD, Prof György Losonczy, MD, Andrzej Kazarnowicz, MD, Keunchil Park, MD, Prof Christian Schumann, MD, Martin Reck, MD, Henrik Depenbrock, MD, Shivani Nanda, MS, Anamarija Kruljac-Letunic, PhD, Raffael Kurek, MD, Luis Paz-Ares, MD, Prof Mark A Socinski, MD, *Lancet Oncol* 2015;16:763-774

2. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-smallcell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, Jürgen R Fischer, Joachim von Pawel, Mariano Provencio, Andrzej Kazarnowicz, György Losonczy, Gilberto de Castro Jr, Aleksandra Szczesna, Lucio Crino, Martin Reck, Rodryg Ramlau, Ernst Ulsperger, Christian Schumann, Jose Elias A Miziara, Álvaro E Lessa, **Mircea Dediu**, Beatrix Bálint, Henrik Depenbrock, Victoria Soldatenkova, Raffael Kurek, Fred R Hirsch, Nick Thatcher, *Lancet Oncol* 2015; 16: 328-337

3. Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer

Joachim von Pawel, Jimmie H. Harvey, David R. Spigel, **Mircea Dediu**, Martin Reck, Cristina L. Cebotaru, Robin C. Humphreys, Matthew J. Gribbin, Norma Lynn Fox, D. Ross Camidge. *Clinical Lung Cancer* 2014, Vol. 15, No. 3, 188-96

4. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed

Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer Luis G. Paz-Ares, Filippo de Marinis, **Mircea Dediu**, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesu's Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H. Zimmermann, Carla Visseren-Grul, and Cesare Gridelli. *J Clin Oncol* 2013; 31: 2895-2902

5. International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1  
  
Giorgio V. Scagliotti, Ihor Vynnychenko, Yukito Ichinose, Kaoru Kubota, Fiona Blackhall, Robert Pirker, Rinat Galiulin, Tudor-Eliade Ciuleanu, Oleksandr Sydorenko, **Mircea Dediu**, Zsolt Papai-Szekely, Natividad Martinez Banaclocha, Sheryl McCoy, Bin Yao, Yong-jiang Hei, Francesco Galimi and David R. Spigel. *J Clin Oncol* 2012; 30:2829-2836
6. Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study  
  
Glenwood D. Goss, Andrew Arnold, Frances A. Shepherd, **Mircea Dediu**, Tudor-Eliade Ciuleanu, David Fenton, Mauro Zukin, David Walde, Francis Laberge, Mark D. Vincent, Peter M. Ellis, Scott A. Laurie, Keyue Ding, Eliot Frymire, Isabelle Gauthier, Natasha B. Leighl, Cheryl Ho, Jonathan Noble, Christopher W. Lee, Lesley Seymour *J Clin Oncol* 2010 ; 1: 49-55.
7. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.  
  
Roila F, Rolski J, Ramlau R, **Dediu M**, Russo MW, Bandekar RR, Grunberg SM..*Ann Oncol.* 2009; 20: 1867-1873.
8. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. Gatzemeier U, Ciuleanu T, **Dediu M**, Ganea-Motan E, Lubenau H, Del Giglio A. *J Thorac Oncol.* 2009 Jun;4(6):736-40.
9. Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer.  
Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, **Dediu M**, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.  
  
*J Clin Oncol.* 2009 ; 1: 4787-4792.
10. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, **Dediu M**, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ.  
  
*J Thorac Oncol.* 2008 Jun;3(6):623-30.
11. Erlotinib in previously treated non-small-cell lung cancer.  
Shepherd F, Rodrigues P, Ciuleanu TT, Tan E, Hirsh V, Sumitra T, Campos D, Maloekoonpiroj S, Smyle M, Martins R, van Kooten M, **Dediu M**, et al.  
  
*The New England Journal of Medicine*, 2005; 353 :123-132

### ***Principal investigator, national clinical trials***

1. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: Results of a prospective observational study.  
**Dediu M**, Crisan E, Radut M, Tarlea A, Median D, Alexandru A, Vremes G, Gal C.  
*Lung Cancer. 2009; 63: 271-276*
2. Split course radiation with concurrent Vinorelbine (NVB) and Cisplatin (CDDP) in locally advanced Non-Small Cell Lung Cancer (NSCLC). A phase II study  
**M. Dediu**, A. Tarlea, P. Iorga, M. Radut, A. Alexandru, G. Miron, C. Cornila.  
*Journal of BUON 2004; 9: 167-172.*
3. A comparative evaluation of surgery followed by adjuvant chemo-radiation versus neoadjuvant chemotherapy followed by concurrent chemo-radiation, for stage III A non-small cell lung cancer (NSCLC). A multi institutional study.  
**M. Dediu**, Teodor Horvat, Alin Tarlea, Emilia Crisan, Mirela Movanu, Alexandru Nicodin, Polixenia Iorga, Maria Radut  
*Journal of BUON Vol 6, No 1, pp : 29-35, 2001.*
4. High dose cisplatin and concurrent radiation therapy in stage III A non-small cell lung cancer.  
**M. Dediu**, A. Tarlea, R. Anghel, M. Radut, E. Crisan. *Journal of B.U.ON. ( Official Journal of the Balkan Union of Oncology) Volume 5, No 1, pp 17-24, 2000.*